{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T00:37:16Z","timestamp":1759624636052,"version":"build-2065373602"},"reference-count":5,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH1710576"],"award-info":[{"award-number":["W81XWH1710576"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.eururo.2022.08.024","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T07:29:54Z","timestamp":1662622194000},"page":"659","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Re: Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Gu\u00e9rin-na\u00efve High-risk Nonmuscle-invasive Bladder Cancer"],"prefix":"10.1016","volume":"82","author":[{"given":"Mehraban","family":"Kavoussi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali A.","family":"Nasrallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen B.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2022.08.024_b0005","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/JU.0000000000002740","article-title":"Sequential intravesical gemcitabine and docetaxel for bacillus Calmette-Gu\u00e9rin-na\u00efve high-risk nonmuscle-invasive bladder cancer","volume":"208","author":"McElree","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2022.08.024_b0010","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.euf.2019.04.002","article-title":"Recurrence rate and cost consequence of the shortage of bacillus Calmette-Guerin Connaught strain for bladder cancer patients","volume":"7","author":"Ourfali","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2022.08.024_b0015","doi-asserted-by":"crossref","first-page":"912438","DOI":"10.3389\/fsurg.2022.912438","article-title":"Novel intravesical therapeutics in the treatment of non-muscle invasive bladder cancer: horizon scanning","volume":"9","author":"Ward","year":"2022","journal-title":"Front Surg"},{"key":"10.1016\/j.eururo.2022.08.024_b0020","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00345-021-03908-x","article-title":"Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage","volume":"40","author":"Balasubramanian","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2022.08.024_b0025","doi-asserted-by":"crossref","first-page":"e213800","DOI":"10.1001\/jamanetworkopen.2021.3800","article-title":"Estimated costs and long-term outcomes of patients with high-risk non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin in the Veterans Affairs health system","volume":"4","author":"Williams","year":"2021","journal-title":"JAMA Netw Open"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382202615X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382202615X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:11:53Z","timestamp":1759583513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030228382202615X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":5,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S030228382202615X"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2022.08.024","relation":{},"ISSN":["0302-2838"],"issn-type":[{"type":"print","value":"0302-2838"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re: Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Gu\u00e9rin-na\u00efve High-risk Nonmuscle-invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2022.08.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}